Physician profile
Roxanne Cech
NPI 1497830566
$3,054.25
in general payments reported to CMS, 2019-2025
30 companies · $256 in 2025
The $256 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $198 · 2020: $97.62 · 2021: $246 · 2022: $533 · 2023: $847 · 2024: $876 · 2025: $256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,979.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,978.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $463.13 | 2019-2025 | Farxiga, Airsupra |
| Lilly USA, LLC | $386.13 | 2021-2025 | Zepbound, Jardiance, Mounjaro |
| Exact Sciences Corporation | $335.45 | 2023-2025 | Cologuard Collection Kit |
| Abbvie INC. | $225.11 | 2021-2024 | Ubrelvy, Qulipta, Vraylar |
| Boston Scientific Corporation | $222.51 | 2020-2025 | Watchman Access System |
| Amgen INC. | $163.96 | 2021-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $160.19 | 2021-2024 | Ozempic, Rybelsus |
| Astellas Pharma US INC | $138.32 | 2022-2024 | Veozah, Myrbetriq |
| Biohaven Pharmaceutical Holding Company Ltd. | $128.25 | 2022 | |
| Xeris Pharmaceuticals, INC. | $112.01 | 2023-2025 | Gvoke Hypopen |
| E.R. Squibb & Sons, L.L.C. | $104.81 | 2022-2024 | Camzyos, Eliquis |
| Dexcom, INC. | $71.73 | 2021-2024 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $60.78 | 2023-2024 | Rexulti |
| Eisai INC. | $60.07 | 2024 | |
| Pfizer INC. | $57.36 | 2022-2023 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.69 | 2022-2024 | Ofev, Jardiance |
| Novartis Pharmaceuticals Corporation | $51.39 | 2022-2023 | |
| Amarin Pharma, INC. | $31.83 | 2019-2020 | |
| Digestive Care, INC. | $29.14 | 2024 | Pertzye |
| Ultragenyx Pharmaceutical INC. | $28.24 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $22.01 | 2021 | |
| Alexion Pharmaceuticals, INC. | $21.77 | 2021 | |
| Inspire Medical Systems, INC. | $20.65 | 2025 | Inspire |
| Horizon Therapeutics Plc | $19.65 | 2021 | |
| Medtronic, INC. | $16.60 | 2023 | Minimed 770g |
| Phathom Pharmaceuticals, INC. | $14.50 | 2024 | Voquezna |
| Janssen Pharmaceuticals, INC | $14.49 | 2020 | |
| Glaxosmithkline, LLC. | $14.32 | 2024 | Shingrix, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.70 | 2023 | Xifaxan |
| Ethicon US, LLC | $11.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roxanne Cech listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.